An urticarial drug eruption caused by tofacitinib for alopecia universalis
April 2019
in “Dermatologic Therapy”
TLDR A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
The article reported a case of drug-induced urticaria in a 21-year-old male patient with alopecia universalis (AU) who was treated with tofacitinib, an oral Janus kinase (JAK) 1/3-inhibitor. The patient had a long-standing history of AU and had not responded to previous treatments. After starting tofacitinib, he experienced hair regrowth within 8 weeks. However, after 14 weeks of treatment, he developed intensely pruritic, erythematous, migratory wheals on his forearms and legs, which were managed with oral cetirizine and topical betamethasone dipropionate. Despite the urticarial reaction, the patient chose to continue tofacitinib due to the significant hair regrowth. The article suggests that while tofacitinib shows promise for hair regrowth in AU, clinicians should be aware of the potential for urticarial drug eruptions as an adverse effect. The mechanism by which tofacitinib causes urticaria is not fully understood and warrants further investigation.
View this study on onlinelibrary.wiley.com →
Cited in this study
research Role of janus kinase inhibitors in the treatment of alopecia areata
Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.
research JAK inhibitors in dermatology: The promise of a new drug class
JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
Related
research Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth
Tofacitinib helped a woman with total-body hair loss grow her hair back.
research Alopecia Areata Flare Patterns in Children and Young Adults on Systemic Tofacitinib
Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.
research Experience with oral tofacitinib in severe alopecia areata with different clinical responses
Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
research Alopecia universalis. Partial response to tofacitinib
Tofacitinib partially improved hair regrowth in a patient with severe hair loss.
research Brazilian Experience of the Treatment of Alopecia Universalis with the Novel Antirheumatic Therapy Tofacitinib: A Case Series
Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.
research Excellent response to tofacitinib treatment in a patient with alopecia universalis
A patient with complete hair loss regrew all her hair using tofacitinib.